Merck's View On The Challenges Of Ebola Vaccination In The DRC

With the latest Ebola outbreak threatening to spread across the Democratic Republic of Congo and beyond, efforts are being stepped up to vaccinate the at-risk population and health workers with Merck Sharp & Dohme’s experimental vaccine, V920. MSD’s Mel Kohn spoke to the Pink Sheet about the development of the vaccine, the experience gained from its use to date, and the difficulties involved in getting the vaccine to those who need it.

Ebola
Merck's Ebola vaccine is being used in the latest outbreak in central Africa • Source: Shutterstock

The number of cases of Ebola virus infection continues to grow in Africa’s second-largest country, the Democratic Republic of Congo (DRC), and vaccination efforts are again being stepped up in an effort to stem the latest outbreak of the disease.

The ninth Ebola outbreak in the DRC ended in July, but the following month another one was declared, this time mainly affecting the province of North Kivu

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Vaccines

More from Pink Sheet